Professor Stephen Neidle
Emeritus Professor of Chemical Biology and CRUK Professorial Fellow
- Principal Investigator of UCL Technology Fund project in pancreatic cancer treatment
- Editor-in-Chief of "Bioorganic and Medicinal Chemistry Letters"
- Member of the editorial boards of "Nucleic Acids Research", "Methods" and "Scientific Reports"
- Member of The Royal Society Newton Advanced Fellowship Panel and the Drinkaware UK Medical Advisory Panel
- Currently member of scientific review panels in Sweden, Republic of Ireland
- The chemistry and biology of nucleic acid structure and recognition by small molecules
- Exploiting this information for the rational design, discovery and development of new anti-cancer and anti-infective agents
- Biological and Medicinal Chemistry Sector Prize, Royal Society of Chemistry, 2000
- Interdisciplinary Award of the Royal Society of Chemistry, 2002
- Avantis Prize in Medicinal Chemistry, 2004
- Sosnovsky Award in Cancer Therapy, 2009
DSc, ARCS, DIC (Imperial College London), FRSC
Stephen Neidle’s interests are primarily in the chemistry and biology of nucleic acid structure and recognition by small molecules, and in exploiting this information for the rational design of novel anti-cancer and anti-infective agents. He has pioneered studies on the structure and recognition of G-quadruplex nucleic acids as therapeutic targets, using an integrated multi-disciplinary approach. He has published over 500 papers and reviews, together with 14 patents, and has written and edited a number of books on nucleic acids, drug-DNA interactions and cancer drug discovery. His current h index is 86 in Web of Science and 98 in Google Scholar.
An example of his work being translated into new therapeutic agents is given by a novel antibiotic (ridinilazole: SMT19969) directly derived from and closely related to, earlier compounds invented by him, in collaboration with Professor John Mann (formerly at Queen’s University Belfast).
Summit plc, an Oxford, UK based drug discovery company, commenced a Phase I clinical trial for ridinilazole in 2012. This orally-available small-molecule antibiotic is selective for the treatment of C. difficile infection, a serious hospital-associated bacterial disease especially affecting the elderly. It is notoriously hard to treat with existing drugs. The Phase I trial of ridinilazole was concluded in 2013, with very successful results. A subsequent successful proof of concept Phase II clinical trial has shown significant superiority over the current agent of choice and Summit Therapeutics is currently planning large-scale Phase III trials for 2018. Ridinilazole has been granted Fast Track designation by the US Food and Drug Administration. The drug was developed by Summit and its biological properties were characterized in a collaboration with the Neidle laboratory, funded by the Wellcome Trust Seeding Drug Discovery fund (see Mann et al, Medchemcomm. 2015, 6:1420-1426).
Work in the Neidle laboratory in the cancer therapeutics area is currently focussed on exploiting the occurrence of quadruplex DNA and RNA sequences in particular regions of the human genome associated with oncogene expression, and targeting these with selective small molecules. Recent studies are applying this approach to therapeutic areas of high unmet clinical need, especially to pancreatic cancers. Lead compounds have been identified which show high activity in in vivo models for pancreatic cancer and are currently being evaluated for further pre-clinical and clinical development, with support from the UCL Technology Fund (see Journal of Medicinal Chemistry, 2018, 61:2500-2517).
The role of quadruplexes in other therapeutic areas is also being pursued. A recent collaboration with Professor Adrian Isaacs (Institute of Neurology, UCL) and Professors David Boykin and David Wilson (Georgia State University, Atlanta, USA) has focussed on the incurable neurodegenerative disorder ALS (amyotrophic lateral sclerosis). The expansion of a GGGGCC repeat within the first intron of the C9orf72 gene is the most common genetic cause of ALS. Several small molecules have been identified that stabilise RNA quadruples formed within the intron, and which ameliorate the key pathologies associated with C9orf72 ALS. This provides proof of principle in vitro and in vivo that targeting GGGGCC repeat quadruplexes has therapeutic potential - see Simone et al, EMBO Molecular Medicine, 2018, 10(1):22-31.
Professor Stephen Neidle is a chemistry graduate of Imperial College, where he also undertook research on the structures of a number of complex natural products and antibiotics (DSc, PhD, ARCS). After a period as an ICI Fellow, he joined the Biophysics Department at King’s College London, which initiated his interest in nucleic acid structural studies. He was one of the first Cancer Research Campaign Career Development Awardees, and has been a Life Fellow and Professorial Fellow of Cancer Research UK since 1986. His work has been recognised by a number of awards, including the Sosnovsky and Aventis Prizes for work on the medicinal chemistry of cancer, the Interdisciplinary and Medicinal Chemistry Awards of the Royal Society of Chemistry and the Paul Ehrlich, Kelland and Guggenheim Lectureships.
He was appointed to the Chair of Biophysics at the Institute of Cancer Research in 1990 (where he was also Academic Dean 1997-2002) and moved to the School of Pharmacy, University of London in 2002 as the first holder of the new Chair of Chemical Biology. He has also been Research Director of the School.
Stephen Neidle is Editor-in-Chief of "Bioorganic and Medicinal Chemistry Letters", and is a member of the editorial boards of the journals "Nucleic Acids Research," "Scientific Reports" and "Methods". He chairs the editorial board of "Annual Reports in Medicinal Chemistry" (2016-) and was Chairman of the Editorial Boards of Tetrahedron Journals 2011-13 and the RSC Biomolecular Sciences book series. He was Chair of the Chemistry in Cancer Research Working Group, American Association for Cancer Research, 2011-12. He is currently a member of The Royal Society Newton Advanced Fellowships Panel and of the “Drinkaware UK” Medical Advisory Panel.